Components:
Method of action:
Treatment option:
Medically reviewed by Oliinyk Elizabeth Ivanovna, PharmD. Last updated on 29.03.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Bucel
Buserelin
hormone-dependent prostate cancer,
breast cancer,
endometriosis (pre-and postoperative periods),
uterine fibroids,
endometrial hyperplastic processes,
infertility treatment (during the in vitro fertilization (IVF) program.
Prostate cancer (testosterone-dependent).
In/m.
In breast cancer and hormone-dependent prostate cancer Bucel FS is administered at a dose of 3.75 mg (1 injection) i / m every 4 weeks. long - term under the supervision of a doctor.
In the treatment of endometriosis, endometrial hyperplastic processes the drug is administered at a dose of 3.75 mg / m once every 4 weeks. Treatment should begin in the first five days of the menstrual cycle. The duration of treatment is 4-6 months.
In the treatment of uterine fibroids Bucel FS is administered at a dose of 3.75 mg / m once every 4 weeks. Treatment should begin in the first five days of the menstrual cycle. The duration of treatment before surgery is 3 months, in other cases-6 months.
In the treatment of infertility by IVF Bucel FS is administered at a dose of 3.75 mg (1 injection) I / m once at the beginning of the follicular (on the 2nd day of the menstrual cycle) or in the middle of the luteal phase (21-24 days) of the menstrual cycle preceding stimulation. After the blockade of pituitary function, as evidenced by a decrease in the concentration of estrogen in the blood serum of at least 50% from baseline (usually defined 12-15 days after injection Bucel FS), in the absence of ovarian cysts (according to US), the endometrial thickness of 5 mm starts stimulation of superovulation gonadotropic hormones under ultrasound monitoring and control of the level of estradiol in serum
Rules for the preparation of suspension and administration of the drug
1. The drug is administered only intramuscularly.
2. The suspension for intravenous injection is prepared immediately before administration using the supplied solvent.
3. The drug should be prepared and administered only by specially trained medical personnel.
4. The bottle with Bucel FS should be held strictly vertically. Easily tapping on the bottle, ensure that all the lyophilizate is at the bottom of the bottle (Fig. 1).
Figure 1. Correct position of the drug bottle.
5. Open the syringe, attach a 1.2 x 50 mm needle to it to take the solvent.
6. Open the ampoule with solvent and fill the syringe with all the contents of the ampoule, set the syringe to a dose of 2 ml (Fig. 2, 3, 4).
Figure 2. The opening of the vial with the solvent.
Figure 3. Procedure for taking the contents of the ampoule into the syringe.
Figure 4. Rules for setting the required amount of liquid in the syringe.
7. Remove the plastic cap from the bottle containing the lyophilizate. Disinfect the rubber stopper of the bottle with an alcohol swab (Fig. 5).
Figure 5. Preparation and disinfection of the bottle cap with the drug.
8. Insert the needle into the bottle of lyophilizate through the center of the rubber stopper and carefully insert the solvent along the inner wall of the bottle, without touching the contents of the bottle with the needle. Remove the syringe from the bottle (fig. 6).
Figure 6. Introduction of the solvent into the vial with the drug.
9. The bottle should remain stationary until the lyophilizate is completely soaked with the solvent and a suspension is formed (for about 3-5 minutes). Then, without turning the bottle, check for the presence of dry lyophilizate at the walls and bottom of the bottle. If dry residues of lyophilizate are detected, leave the bottle until completely soaked (Fig. 7).
Figure 7. Checking the presence of dry residue in the bottle.
10. After the dry lyophilizate remains have disappeared, the contents of the bottle should be carefully mixed in a circular motion for 30-60 seconds until a homogeneous suspension is formed. Do not turn or shake the bottle (fig. 8).
Figure 8. Preparation of a homogeneous suspension (slow rotation of the bottle).
11. Quickly insert the needle through the rubber stopper into the bottle. Then lower the needle section down and, tilting the bottle at an angle of 45°, slowly fill the entire suspension into the syringe (Fig. 9).
Figure 9. The procedure for taking the drug into the syringe.
12. Do not turn the bottle over when typing. A small amount of the drug may remain on the walls and bottom of the bottle. The consumption for the residue on the walls and bottom of the bottle is taken into account (Fig. 10).
Figure 10. The correct position of the bottle when taking the drug into the syringe.
13. Immediately after the solution set, remove the needle. Replace with a 0.8×40 mm needle, carefully turn the syringe over and remove the air from the syringe (Fig. 11).
Figure 11. Method of removing air from the syringe.
14. The Bucel FS suspension should be administered immediately after preparation.
15. Use an alcohol swab to disinfect the injection site. Insert the needle deep into the gluteal muscle, then pull the plunger of the syringe slightly back to make sure that there is no damage to the vessel. Enter the suspension slowly, with constant pressure on the plunger of the syringe. If the needle is clogged, replace it with another needle of the same diameter.
16. For repeated injections, the left and right sides should be alternated.
The first 7 days — n/a 500 mcg 3 times a day (every 8 hours). From the 8th day, they switch to intranasal administration: 2 doses before and after breakfast, lunch and dinner. With confirmed hormone-dependent prostate tumors, the course can last a lifetime.
A single dose of the drug when the pump is fully pressed is 150 mcg.
In the treatment of endometriosis, uterine fibroids, endometrial hyperplastic processes: the drug is injected into the nasal passages after their purification at a dose of 900 mcg/day. The daily dose of the drug is administered in equal portions, one injection into each nasal passage 3 times a day at regular intervals (6-8 hours) in the morning, afternoon and evening. Treatment with Bucel should be started on the first or second day of the menstrual cycle, the administration is continuous throughout the course of treatment. The course of treatment is 4-6 months.
In the treatment of infertility by in vitro fertilization (IVF): Bucel spray is administered intranasally by one injection (150 mcg) in each nostril 3-4 times a day at regular intervals. The daily dose is 900-1200 mcg. Bucel is prescribed at the beginning of the follicular (on the 2nd day of the menstrual cycle) or in the middle of the luteal phase (21-24 days) of the menstrual cycle preceding stimulation. Via 14-17 days with a decrease estradiol in the serum of patients by at least 50% from baseline, the absence of cysts in the ovaries, the endometrium thickness not exceeding 5 mm starts stimulation of superovulation gonadotropic hormones under ultrasound monitoring and control of the level of estradiol in serum. If necessary, the Bucel dose can be adjusted
hypersensitivity to the components of the drug,
pregnancy,
lactation period.
Hypersensitivity.
Allergic reactions: urticaria, hyperemia of the skin, rarely-angioedema.
From the central nervous system: frequent mood swings, sleep disturbances, depression, headache.
From the musculoskeletal system: with long-term use-demineralization of bones with the risk of developing osteoporosis.
In women-headache, depression, sweating and changes in libido, dryness of the vaginal mucosa, pain in the lower abdomen, rarely-menstrual-like bleeding (during the first weeks of treatment).
In men, in the treatment of prostate cancer-during the first 2-3 weeks after the first injection, buserelin can cause exacerbation and progression of the underlying disease (associated with stimulating the synthesis of gonadotropins and, accordingly, testosterone), gynecomastia, possible flushes of blood to the face, increased sweating and decreased potency (rarely requires discontinuation of therapy), a transient increase in the concentration of androgens in the blood, urinary retention, renal edema-edema of the face, eyelids, legs, muscle weakness in the lower extremities. At the beginning of treatment of patients with prostate cancer, there may be a temporary increase in bone pain, in this case, symptomatic therapy should be carried out. Isolated cases of ureteral obstruction and spinal cord compression have been recorded
Other: in isolated cases (the causal relationship is not clearly established) - pulmonary embolism, dyspeptic disorders.
Nausea, vomiting, abdominal pain, rarely-gynecomastia, impotence, decreased libido, thrombosis, in patients with bone pain, they may increase.
No overdose cases have been reported at this time.
A synthetic analogue of the endogenous GnRH. Buserelin competitively binds to the receptors of the cells of the anterior pituitary gland, causing a short-term increase in the level of sex hormones in the blood plasma, which later leads to a complete reversible blockade of the gonadotropic function of the pituitary gland, thus inhibiting the release of LH and FSH. As a result, there is a suppression of the synthesis of sex hormones in the gonads, which is manifested by a decrease in the concentration of estradiol in the blood plasma to post-menopausal values in women and a decrease in the content of testosterone to the post-castration level in men. After the first administration of buserelin by the 21st day in men, the concentration of testosterone decreases to the post-castration level (characteristic of the state of orchidectomy), t.e. pharmacological castration is called. And in women, the concentration of estradiol decreases to the level corresponding to ovariectomy or postmenopause
The concentration of testosterone and estradiol remains reduced during the entire period of treatment, carried out every 28 days, which leads to inhibition of growth and the reverse development of hormone-dependent tumors. After discontinuation of treatment, the physiological secretion of hormones is restored.
Bioavailability is high. Cmax In plasma, it is reached approximately 2-3 hours after intravenous administration and remains at a level sufficient to inhibit the synthesis of gonadotropins by the pituitary gland for at least 4 weeks.
It is well resorbed through the nasal mucosa, creating sufficiently high concentrations in the blood plasma.
- Antitumor agent, gonadotropin-releasing hormone analog (GnRH) [Hormones of the hypothalamus, pituitary gland, gonadotropins and their antagonists]
- Antitumor agent, gonadotropin-releasing hormone analog (GnRH) [Antitumor hormonal agents and Hormone antagonists]
- Antitumor hormonal agents and hormone antagonists
- An antitumor agent, an analogue of gonadotropin-releasing hormone [Hormones of the hypothalamus, pituitary gland, gonadotropins and their antagonists]
- Antitumor agent, an analog of gonadotropin-releasing hormone [Antitumor hormonal agents and hormone antagonists]
Concomitant use of Bucel FS with drugs containing sex hormones (for example, in the ovulation induction mode) may contribute to the occurrence of ovarian hyperstimulation syndrome.
With the simultaneous use of Bucel, FS may reduce the effectiveness of hypoglycemic agents.
